Cargando…
HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer’s disease in a three cohorts study
Several retrospective epidemiological studies report that utilization of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) inhibitors called statins at mid-life can reduce the risk of developing sporadic Alzheimer’s disease (AD) by as much as 70%. Conversely, administration of these inhibitors in cli...
Autores principales: | Leduc, Valerie, De Beaumont, Louis, Théroux, Louise, Dea, Doris, Aisen, Paul, Petersen, Ronald C., Dufour, Robert, Poirier, Judes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318698/ https://www.ncbi.nlm.nih.gov/pubmed/25023145 http://dx.doi.org/10.1038/mp.2014.81 |
Ejemplares similares
-
Function and Comorbidities of Apolipoprotein E in Alzheimer's Disease
por: Leduc, Valérie, et al.
Publicado: (2011) -
Association of HMGCR polymorphism with late-onset Alzheimer's disease in Han Chinese
por: Chang, Xiao-Long, et al.
Publicado: (2016) -
EEG oscillations during word processing predict MCI conversion to Alzheimer's disease
por: Mazaheri, Ali, et al.
Publicado: (2017) -
Anti-HMGCR Myopathy
por: Mohassel, Payam, et al.
Publicado: (2018) -
An MRI-Derived Definition of MCI-to-AD Conversion for Long-Term, Automatic Prognosis of MCI Patients
por: Aksu, Yaman, et al.
Publicado: (2011)